Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient ...

Alvotech and UK-based Advanz Pharma sign agreement to commercialise three additional biosimilar candidates in Europe.

A new NDA was submitted in January 2024, which the FDA did accept, and that was later converted into a priority review. An ...

Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting ...

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...

The HSS has terminated a contract previously awarded to Moderna to help advance a vaccine candidate targeting bird flu.

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Expanding the reach of CAR-T therapeutics could unlock promising new treatment possibilities for solid tumour patients.